Literature DB >> 19392659

Characterization of SENP7, a SUMO-2/3-specific isopeptidase.

Lin Nan Shen1, Marie-Claude Geoffroy, Ellis G Jaffray, Ronald T Hay.   

Abstract

The modification of proteins by SUMO (small ubiquitin-related modifier) plays important roles in regulating the activity, stability and cellular localization of target proteins. Similar to ubiquitination, SUMO modification is a dynamic process that can be reversed by SENPs [SUMO-1/sentrin/SMT3 (suppressor of mif two 3 homologue 1)-specific peptidases]. To date, six SENPs have been discovered in humans, although knowledge of their regulation, specificity and biological functions is limited. In the present study, we report that SENP7 has a restricted substrate specificity, being unable to process SUMO precursors and displaying paralogue-specific isopeptidase activity. The C-terminal catalytic domain of SENP7 efficiently depolymerized poly-SUMO-2 chains but had undetectable activity against poly-SUMO-1 chains. SENP7 also displayed isopeptidase activity against di-SUMO-2- and SUMO-2-modified RanGAP1 (Ran GTPase-activating protein 1) but had limited activity against SUMO-1-modified RanGAP1. in vivo, full-length SENP7 was localized to the nucleoplasm and preferentially reduced the accumulation of high-molecular-mass conjugates of SUMO-2 and SUMO-3 compared with SUMO-1. Small interfering RNA-mediated ablation of SENP7 expression led to the accumulation of high-molecular-mass SUMO-2 species and to the accumulation of promyelocytic leukaemia protein in subnuclear bodies. These findings suggest that SENP7 acts as a SUMO-2/3-specific protease that is likely to regulate the metabolism of poly-SUMO-2/3 rather than SUMO-1 conjugation in vivo.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19392659     DOI: 10.1042/BJ20090246

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  46 in total

Review 1.  The fate of metaphase kinetochores is weighed in the balance of SUMOylation during S phase.

Authors:  Debaditya Mukhopadhyay; Mary Dasso
Journal:  Cell Cycle       Date:  2010-08-09       Impact factor: 4.534

Review 2.  Cardiac function and disease: emerging role of small ubiquitin-related modifier.

Authors:  Jun Wang
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2010-12-31

3.  In Vitro Studies Reveal a Sequential Mode of Chain Processing by the Yeast SUMO (Small Ubiquitin-related Modifier)-specific Protease Ulp2.

Authors:  Julia Eckhoff; R Jürgen Dohmen
Journal:  J Biol Chem       Date:  2015-04-01       Impact factor: 5.157

Review 4.  SUMO rules: regulatory concepts and their implication in neurologic functions.

Authors:  Mathias Droescher; Viduth K Chaugule; Andrea Pichler
Journal:  Neuromolecular Med       Date:  2013-08-30       Impact factor: 3.843

Review 5.  SUMOylation and deSUMOylation at a glance.

Authors:  Yonggang Wang; Mary Dasso
Journal:  J Cell Sci       Date:  2009-12-01       Impact factor: 5.285

6.  Swapping small ubiquitin-like modifier (SUMO) isoform specificity of SUMO proteases SENP6 and SENP7.

Authors:  Kamela O Alegre; David Reverter
Journal:  J Biol Chem       Date:  2011-08-30       Impact factor: 5.157

7.  Assays for investigating deSUMOylation enzymes.

Authors:  Ikenna G Madu; Yuan Chen
Journal:  Curr Protoc Mol Biol       Date:  2012-07

8.  Identification and characterization of a new chemotype of noncovalent SENP inhibitors.

Authors:  Ikenna G Madu; Andrew T Namanja; Yang Su; Steven Wong; Yi-Jia Li; Yuan Chen
Journal:  ACS Chem Biol       Date:  2013-05-01       Impact factor: 5.100

9.  The SUMO protease SENP6 is essential for inner kinetochore assembly.

Authors:  Debaditya Mukhopadhyay; Alexei Arnaoutov; Mary Dasso
Journal:  J Cell Biol       Date:  2010-03-08       Impact factor: 10.539

Review 10.  A manually curated network of the PML nuclear body interactome reveals an important role for PML-NBs in SUMOylation dynamics.

Authors:  Ellen Van Damme; Kris Laukens; Thanh Hai Dang; Xaveer Van Ostade
Journal:  Int J Biol Sci       Date:  2010-01-12       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.